Hospital-Managed CAP with Pseudomonas aeruginosa Risk Factors in Adults
This protocol covers adults (age 18 or older) hospitalised with community-acquired pneumonia who have locally validated risk factors for Pseudomonas aeruginosa. Standard CAP treatment is insufficient for this subgroup — a targeted modification is required.
Clinical Scenario
Empiric anti-pseudomonal coverage is indicated when one or more of the following locally validated risk factors are present:
- Prior respiratory isolation of P. aeruginosa
- Recent hospitalisation with parenteral antibiotic exposure in the last 90 days
Guidelines recommend covering empirically for P. aeruginosa only when such locally validated risk factors are confirmed — prior respiratory isolation and recent parenteral antibiotic use are the most consistently strong individual predictors.
Treatment Approach
The strategy modifies the standard CAP regimen by adding empiric coverage for P. aeruginosa using one of several established anti-pseudomonal agents, alongside culture collection to enable de-escalation or to confirm the need for continued targeted therapy.
Specific agent selection and the full evidence-based regimen — including sequencing and duration guidance — are available in the complete structured protocol.
Full protocol access below ↓
References
DOI: 10.1164/rccm.201908-1581ST
We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present (strong recommendation, moderate quality of evidence).
The most consistently strong individual risk factors for respiratory infection with MRSA or P. aeruginosa are prior isolation of these organisms, especially from the respiratory tract, and/or recent hospitalization and exposure to parenteral antibiotics.
Empiric treatment options for P. aeruginosa include piperacillin-tazobactam (4.5 g every 6 h), cefepime (2 g every 8 h), ceftazidime (2 g every 8 h), aztreonam (2 g every 8 h), meropenem (1 g every 8 h), or imipenem (500 mg every 6 h).
We believe that the duration of therapy for CAP due to suspected or proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital-acquired pneumonia and ventilator-associated pneumonia guidelines.
View source ↗